Novartis AG (ADR) (NVS), Sanofi SA (ADR) (SNY): Pharma Big Wigs Warm Up to Africa’s $40 Billion Opportunity

Page 1 of 2

For a long time, Africa’s traditional enemy with regard to diseases have been communicable diseases like HIV and Malaria. Now, however, this trend is changing. Prevalence of HIV is on a downtrend and malaria infections in most parts of the continent have dropped significantly. On the flip side, however, non communicable diseases like cancer, high blood pressure, and diabetes are securing root.

The World Health Organization, along with other reputable global health organizations, contends that non communicable diseases accounted for 28% of all deaths in Sub Saharan Africa in 2008. This figure is expected to reach 46% by 2030. In view of this, pharmaceutical spending is expected to rise astronomically moving forward. In 2012, pharmaceutical spending in the continent stood at $18 billion. This figure is expected to reach $40 billion as early as 2020. A growing middle class, coupled with steady economic growth in most parts of the continent, will be the impetus behind the increased spending.

Novartis AG (ADR) (NYSE:NVS)

What does this mean for pharmaceutical big wigs, and in particular Novartis AG (ADR) (NYSE:NVS), Sanofi SA (ADR) (NYSE:SNY), and GlaxoSmithKline plc (ADR) (NYSE:GSK)?

GlaxoSmithKline takes volume over profit approach

Not exactly a hard-nosed business, but GlaxoSmithKline is seeking to increase its presence in the African market at the expense of its margins. GlaxoSmithKline plc (ADR) (NYSE:GSK)’s volume over profit approach, brought to light in mid 2012, has seen the company implement price cuts for some of its key drugs. The goal is to increase its volume five-fold over the next half decade. What’s more is that the initiative is not nested under the company’s charity unit, but has been absorbed into the core business.

As far as social responsibility goes, GlaxoSmithKline plc (ADR) (NYSE:GSK) gets a straight ten out of ten. Business-wise, however, the move has been deemed by watchers as not the wisest from the pharmaceutical heavyweight. In my view, deeming the move to be unwise is at the least myopic. Despite the floundering state of the economy in most parts of the African continent, growth is encouraging. In fact, economic growth over the past ten years in key African economies like Kenya and Nigeria has been between 4%-7%, which is much higher than growth in most developed economies.

This growth goes hand in hand with the rapid development of a strong middle class. In relation to this, more African consumers will have money to spend on the treatment and control of chronic non communicable illnesses moving forward. GlaxoSmithKline plc (ADR) (NYSE:GSK)’s move to enlarge its footprint now will certainly pay off in the long run. The fact that it is also moving its focus away from the austerity-hit Eurozone to emerging markets means that it will place its full weight behind the initiative.

Novartis seeks to enhance continent’s research and development

Novartis AG (ADR) (NYSE:NVS), on the other hand, is taking a slightly different approach. In February, it announced a joint initiative with The University Of Cape Town (UCT) that would help pass on the skills needed to treat communicable diseases, which, despite decreasing over the years, still remains a thorn in the flesh of African society. Under the joint initiative, Novartis AG (ADR) (NYSE:NVS) and UCT will enhance the skill set of African medical professionals and improve the continent’s Research and Development, which is critically important for health care. This collaboration will lead to the development of an FDA-level clinic study site in South Africa. The clinic will particularly work on medicines against Tuberculosis and facilitate research on malaria.

Through this move, Novartis AG (ADR) (NYSE:NVS) will not only be able to grow its investment in Africa moving forward, but it will also be able to give back to society. From my understanding, this will act as an incentive for distributors and by extension consumers, as well.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The Top 10 States With Fastest Internet Speeds

10 Best Places to Visit in USA in August

Top 10 Cities to Visit Before You Die

Top 10 Genetically Modified Food In the US

15 Highest Grossing Movies Opening Weekend

5 Best Poker Books For Beginners

10 Strategies Hedge Funds Use to Make Huge Returns

Top 10 Fast Food Franchises to Buy

10 Best Places to Visit in Canada

Best Summer Jobs for Teachers

10 Youngest Hedge Fund Billionaires

Top 10 One Hit Wonders of the 90s

Fastest Growing Cities In America

Top 10 U.S. Cities for Freelancers

Top 9 Most Popular Free iPhone Apps

Top 10 Least Expensive Private Business Schools in the US

Top 15 Most Expensive Countries in the World – 2014

Top Businesses to Invest In

Top 5 Things You Might Be Doing Wrong With Your Business

Top 5 Strategic Technology Trends in 2014

Top Rags to Riches Stories

Parenting Behavior That Promotes Future Leaders

Top 5 Mistakes Made by Small Businesses

Top 5 Most Common and Potentially Devastating Financial Blunders

Top 5 Highest Paying Jobs for Web Designers

Top 6 Most Respected Professions that Also Pay Well

Top 5 Pitfalls Investors Should Avoid

Top 6 Lawyers and Policy Makers Under 30

Top 6 New Year’s Resolutions for Entrepreneurs

Top 7 Locations to Check in on Facebook

Top 5 Mistakes made by Rookie eBay Sellers

Top 7 eBook Publishers in 2013

Top 6 Health Industry Trends in 2014

5 Lessons for Entrepreneurs from Seth Godin

Top 5 Success Tips from Jordan Belfort – the Wolf of Wall Street

Best Master’s in Finance Degree Programs

Top 6 Earning Celebrities Over 50

The most expensive sports to play

Top 7 Earning Celebrities Under 25

Best 7 Online Courses to Take: Free Finance MOOCs

Top 6 Bad Habits that Promote Failure

20 Most Valuable Soccer Teams in the World in 2013

12 Most Expensive Countries for Foreign Students

Top 30 Most Influential Women in the World

Top 20 Most Expensive New Year Eve Shows

Top 5 Best Vocational Careers

Top 10 Jobs for 2014 by Salary Gain (Predictions)

Top 5 Digital Trends for 2014

Top 6 Things You Can Do To Increase Your Productivity

Top 9 Trending Smartphones in 2013

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!